Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Killing the two deadly birds of atherosclerosis and cancer with one stone

Nature Cardiovascular Research volume 1, pages 403–404 (2022)Cite this article

Subjects

Recognition of mechanistic similarities and the interconnection between cardiovascular disease and cancer in recent years offers an opportunity to think more creatively about therapeutic development. Targeting shared pathways, either through drug repurposing or novel compounds, holds the promise of addressing both afflictions at the same time.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Common pathways in cancer and atherosclerosis.

References

  1. GDB 2017 Causes of Death Collaborators. Lancet 392, 1736–1788 (2018).

  2. Lau, E. S. et al. JACC CardioOncol. 3, 48–58 (2021).

    Article  Google Scholar 

  3. Rasmussen-Torvik, L. J. et al. Circulation 127, 1270–1275 (2013).

    Article  Google Scholar 

  4. Ogunmoroti, O. et al. J. Am. Heart Assoc. 5, e003954 (2016).

    Article  Google Scholar 

  5. Roderburg, C. et al. ESC Heart Fail. 8, 3628–3633 (2021).

    Article  Google Scholar 

  6. Paterson, D. I. et al. JACC CardioOncol. 4, 85–94 (2022).

    Article  Google Scholar 

  7. Meijers, W. C. et al. Circulation 138, 678–691 (2018).

    Article  CAS  Google Scholar 

  8. Avraham, C. et al. Circulation 142, 670–683 (2020).

    Article  CAS  Google Scholar 

  9. Koelwyn, G. J. et al. Nat. Med. 26, 1452–1458 (2020).

    Article  Google Scholar 

  10. Ringel, A. E. et al. Cell 183, 1848–1866.e26 (2020).

    Article  CAS  Google Scholar 

  11. Visel, A. et al. Nature 464, 409–412 (2010).

    Article  CAS  Google Scholar 

  12. Ridker, P. M. et al. Lancet 390, 1833–1842 (2017).

    Article  CAS  Google Scholar 

  13. Jarr, K. U. et al. N. Engl. J. Med. 384, 382–383 (2021).

    Article  Google Scholar 

  14. Jaiswal, S. et al. N. Engl. J. Med. 377, 111–121 (2017).

    Article  Google Scholar 

  15. Wang, Y. et al. Proc. Natl Acad. Sci. USA 117, 15818–15826 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA

    Caitlin F. Bell & Nicholas J. Leeper

  2. Department of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA

    Caitlin F. Bell & Nicholas J. Leeper

  3. Stanford Cardiovascular Institute, Stanford, CA, USA

    Caitlin F. Bell & Nicholas J. Leeper

Authors
  1. Caitlin F. Bell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas J. Leeper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas J. Leeper.

Ethics declarations

Competing interests

N.J.L. and C.F.B. are advisors to Bitterroot Bio, a biotechnology company studying vascular inflammation.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bell, C.F., Leeper, N.J. Killing the two deadly birds of atherosclerosis and cancer with one stone. Nat Cardiovasc Res 1, 403–404 (2022). https://doi.org/10.1038/s44161-022-00068-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44161-022-00068-y

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research